Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA

Hideo Hara, Akihiro Mouri, Yoshikazu Yonemitsu, Toshitaka Nabeshima, Takeshi Tabira

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Based on the amyloid cascade hypothesis, many reports have indicated that immunotherapy is beneficial for Alzheimer's disease (AD). We developed a mucosal immunotherapy for AD by nasal administration of recombinant Sendai virus vector carrying Aβ1-43 and mouse IL-10 cDNA. Nasal but not intramuscular administration of the vaccine induced good antibody responses to Aβ. When APP transgenic mice (Tg2576) received this vaccine once nasally, the Aβ plaque burden was significantly decreased 8 weeks after without inducing inflammation in the brain. The amount of Aβ measured by ELISA was also reduced in both soluble and insoluble fractions of the brain homogenates, and notably the Aβ oligomer (12-mer) was also apparently decreased. Tg2576 mice showed significant improvement in cognitive functions examined at 3 months after vaccination. Thus, this is an alternative immunotherapy for AD, which has an advantage in non-invasive, safe and relatively long lasting features.

Original languageEnglish
Pages (from-to)7474-7482
Number of pages9
JournalVaccine
Volume29
Issue number43
DOIs
Publication statusPublished - 06-10-2011
Externally publishedYes

Fingerprint

Sendai virus
immunotherapy
Alzheimer disease
interleukin-10
Interleukin-10
Immunotherapy
Alzheimer Disease
Complementary DNA
animal models
mice
Vaccines
vaccines
intranasal administration
Intranasal Administration
Encephalitis
amyloid
encephalitis
intramuscular injection
Nose
Amyloid

All Science Journal Classification (ASJC) codes

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

@article{94b6660cb8d042139ee98d5c73fce712,
title = "Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA",
abstract = "Based on the amyloid cascade hypothesis, many reports have indicated that immunotherapy is beneficial for Alzheimer's disease (AD). We developed a mucosal immunotherapy for AD by nasal administration of recombinant Sendai virus vector carrying Aβ1-43 and mouse IL-10 cDNA. Nasal but not intramuscular administration of the vaccine induced good antibody responses to Aβ. When APP transgenic mice (Tg2576) received this vaccine once nasally, the Aβ plaque burden was significantly decreased 8 weeks after without inducing inflammation in the brain. The amount of Aβ measured by ELISA was also reduced in both soluble and insoluble fractions of the brain homogenates, and notably the Aβ oligomer (12-mer) was also apparently decreased. Tg2576 mice showed significant improvement in cognitive functions examined at 3 months after vaccination. Thus, this is an alternative immunotherapy for AD, which has an advantage in non-invasive, safe and relatively long lasting features.",
author = "Hideo Hara and Akihiro Mouri and Yoshikazu Yonemitsu and Toshitaka Nabeshima and Takeshi Tabira",
year = "2011",
month = "10",
day = "6",
doi = "10.1016/j.vaccine.2011.07.057",
language = "English",
volume = "29",
pages = "7474--7482",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "43",

}

Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA. / Hara, Hideo; Mouri, Akihiro; Yonemitsu, Yoshikazu; Nabeshima, Toshitaka; Tabira, Takeshi.

In: Vaccine, Vol. 29, No. 43, 06.10.2011, p. 7474-7482.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA

AU - Hara, Hideo

AU - Mouri, Akihiro

AU - Yonemitsu, Yoshikazu

AU - Nabeshima, Toshitaka

AU - Tabira, Takeshi

PY - 2011/10/6

Y1 - 2011/10/6

N2 - Based on the amyloid cascade hypothesis, many reports have indicated that immunotherapy is beneficial for Alzheimer's disease (AD). We developed a mucosal immunotherapy for AD by nasal administration of recombinant Sendai virus vector carrying Aβ1-43 and mouse IL-10 cDNA. Nasal but not intramuscular administration of the vaccine induced good antibody responses to Aβ. When APP transgenic mice (Tg2576) received this vaccine once nasally, the Aβ plaque burden was significantly decreased 8 weeks after without inducing inflammation in the brain. The amount of Aβ measured by ELISA was also reduced in both soluble and insoluble fractions of the brain homogenates, and notably the Aβ oligomer (12-mer) was also apparently decreased. Tg2576 mice showed significant improvement in cognitive functions examined at 3 months after vaccination. Thus, this is an alternative immunotherapy for AD, which has an advantage in non-invasive, safe and relatively long lasting features.

AB - Based on the amyloid cascade hypothesis, many reports have indicated that immunotherapy is beneficial for Alzheimer's disease (AD). We developed a mucosal immunotherapy for AD by nasal administration of recombinant Sendai virus vector carrying Aβ1-43 and mouse IL-10 cDNA. Nasal but not intramuscular administration of the vaccine induced good antibody responses to Aβ. When APP transgenic mice (Tg2576) received this vaccine once nasally, the Aβ plaque burden was significantly decreased 8 weeks after without inducing inflammation in the brain. The amount of Aβ measured by ELISA was also reduced in both soluble and insoluble fractions of the brain homogenates, and notably the Aβ oligomer (12-mer) was also apparently decreased. Tg2576 mice showed significant improvement in cognitive functions examined at 3 months after vaccination. Thus, this is an alternative immunotherapy for AD, which has an advantage in non-invasive, safe and relatively long lasting features.

UR - http://www.scopus.com/inward/record.url?scp=80053439054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053439054&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.07.057

DO - 10.1016/j.vaccine.2011.07.057

M3 - Article

C2 - 21803105

AN - SCOPUS:80053439054

VL - 29

SP - 7474

EP - 7482

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 43

ER -